drugset
drugset / Trial / NCT07062549

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

NCT07062549 ↗

Phase 1 Recruiting 6 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NaSingle-groupOpen-labelOther

Summary

This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan

Timeline

Start
2022-01-26
Primary completion
2027-07
Completion
2029-07

Drugs

EvaluationDrugModalityDoseRoute
Subject 111In-XYIMSR-01 Diagnostic / imaging agent 388.5 mbq Intravenous

Indications

renal cell carcinoma